Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006

Abstract In light of recent reports of osteonecrosis of the jaw (ONJ) in cancer patients whose treatment regimens include an intravenous bisphosphonate, Novartis convened an international advisory board of experts in the fields of oral surgery and pathology, medical oncology, metabolic bone disease,...

Full description

Saved in:

Bibliographic Details
Published in:	Critical reviews in oncology/hematology Vol. 62; no. 2; pp. 148 - 152
Main Authors:	Weitzman, Richard, Sauter, Nicholas, Eriksen, Erik Fink, Tarassoff, Peter G, Lacerna, Leo V, Dias, Rosh, Altmeyer, Anne, Csermak-Renner, Katalin, McGrath, Lynne, Lantwicki, Linda, Hohneker, John A
Format:	Journal Article
Language:	English
Published:	Shannon Elsevier Ireland Ltd 01-05-2007 Elsevier Science
Subjects:	Biological and medical sciences Bisphosphonate compounds Cancer patients Diphosphonates - adverse effects Diseases of the osteoarticular system Guidelines as Topic Hematologic and hematopoietic diseases Hematology, Oncology and Palliative Medicine Humans Jaw Diseases - diagnosis Jaw Diseases - prevention & control Jaw Diseases - therapy Medical sciences Osteonecrosis - diagnosis Osteonecrosis - prevention & control Osteonecrosis - therapy Osteonecrosis of the jaw Osteoporosis - drug therapy Vascular bone diseases Bisphosphonate compounds Cancer patients Osteonecrosis of the jaw Human Jaw Diseases of the osteoarticular system Osteonecrosis Review Malignant tumor Bisphosphonates Recommendation Prevention Cancerology Treatment Diagnosis Bibliographic review Cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract In light of recent reports of osteonecrosis of the jaw (ONJ) in cancer patients whose treatment regimens include an intravenous bisphosphonate, Novartis convened an international advisory board of experts in the fields of oral surgery and pathology, medical oncology, metabolic bone disease, and orthopedics to review existing data and provide updated recommendations on the clinical diagnosis, prevention, and management of ONJ in the oncology setting. Recommendations were developed to help guide healthcare professionals in early diagnosis and patient management. It is recommended that patients be encouraged to receive a dental examination prior to initiating bisphosphonate therapy and, if possible, complete any necessary dental procedures (e.g., tooth extraction) prior to initiating bisphosphonate therapy. Patients should receive regular dental visits during bisphosphonate therapy. Patients should be encouraged to practice good oral hygiene and minimize possible jaw trauma. If possible, patients should avoid dental surgery during treatment with bisphosphonates. If exposed bone is observed or reported in the oral cavity at any time (suspected ONJ), refer the patient to a dental professional immediately.
ISSN:	1040-8428 1879-0461
DOI:	10.1016/j.critrevonc.2006.12.005